A step forward for LRRK2 inhibitors in Parkinson's disease

Patrick A Lewis

doi:10.1126/scitranslmed.abq7374

A step forward for LRRK2 inhibitors in Parkinson's disease

Sci Transl Med. 2022 Jun 8;14(648):eabq7374. doi: 10.1126/scitranslmed.abq7374. Epub 2022 Jun 8.

Author

Patrick A Lewis^{1

2

3}

Affiliations

¹ Royal Veterinary College, London NW1 0TU, UK.
² UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
³ Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.

PMID: 35675432
DOI: 10.1126/scitranslmed.abq7374

Abstract

A phase 1 clinical trial for kinase inhibitors targeting LRRK2 provides the foundation for testing the efficacy of LRRK2 kinase inhibitors in Parkinson's disease.

Publication types

Review
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / genetics
Mutation
Parkinson Disease* / drug therapy

Substances

LRRK2 protein, human
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2